184 related articles for article (PubMed ID: 15967080)
21. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
[TBL] [Abstract][Full Text] [Related]
22. Coexpression of MYC and BCL-2 predicts prognosis in primary gastrointestinal diffuse large B-cell lymphoma.
Xia B; Zhang L; Guo SQ; Li XW; Qu FL; Zhao HF; Zhang LY; Sun BC; You J; Zhang YZ
World J Gastroenterol; 2015 Feb; 21(8):2433-42. PubMed ID: 25741152
[TBL] [Abstract][Full Text] [Related]
23. Transcriptome profiling reveals an integrated mRNA-lncRNA signature with predictive value for long-term survival in diffuse large B-cell lymphoma.
Gao Q; Li Z; Meng L; Ma J; Xi Y; Wang T
Aging (Albany NY); 2020 Nov; 12(22):23275-23295. PubMed ID: 33221755
[TBL] [Abstract][Full Text] [Related]
24. Clinical significance of 'double-hit' and 'double-expression' lymphomas.
Ma Z; Niu J; Cao Y; Pang X; Cui W; Zhang W; Li X
J Clin Pathol; 2020 Mar; 73(3):126-138. PubMed ID: 31615842
[TBL] [Abstract][Full Text] [Related]
25. Revised International Prognostic Index and genetic alterations are associated with early failure to R-CHOP in patients with diffuse large B-cell lymphoma.
Dlouhy I; Karube K; Enjuanes A; Salaverria I; Nadeu F; Ramis-Zaldivar JE; Valero JG; Rivas-Delgado A; Magnano L; Martin-García D; Pérez-Galán P; Clot G; Rovira J; Jares P; Balagué O; Giné E; Mozas P; Briones J; Sancho JM; Salar A; Mercadal S; Alcoceba M; Valera A; Campo E; López-Guillermo A
Br J Haematol; 2022 Feb; 196(3):589-598. PubMed ID: 34632572
[TBL] [Abstract][Full Text] [Related]
26. BCL2 positive and BCL6 negative diffuse large B cell lymphoma patients benefit from R-CHOP therapy irrespective of germinal and non germinal center B cell like subtypes.
Jovanovic MP; Mihaljevic B; Jakovic L; Martinovic VC; Fekete MD; Andjelic B; Antic D; Bogdanovic A; Boricic N; Terzic T; Jelicic J; Milenkovic S
J BUON; 2015; 20(3):820-8. PubMed ID: 26214636
[TBL] [Abstract][Full Text] [Related]
27. Predictive and Prognostic Molecular Factors in Diffuse Large B-Cell Lymphomas.
Pileri SA; Tripodo C; Melle F; Motta G; Tabanelli V; Fiori S; Vegliante MC; Mazzara S; Ciavarella S; Derenzini E
Cells; 2021 Mar; 10(3):. PubMed ID: 33803671
[TBL] [Abstract][Full Text] [Related]
28. MicroRNAs associated to single drug components of R-CHOP identifies diffuse large B-cell lymphoma patients with poor outcome and adds prognostic value to the international prognostic index.
Due H; Brøndum RF; Young KH; Bøgsted M; Dybkær K
BMC Cancer; 2020 Mar; 20(1):237. PubMed ID: 32192453
[TBL] [Abstract][Full Text] [Related]
29. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
30. Immunophenotype as prognostic factor for diffuse large B-cell lymphoma in patients undergoing clinical risk-adapted therapy.
Veelken H; Vik Dannheim S; Schulte Moenting J; Martens UM; Finke J; Schmitt-Graeff A
Ann Oncol; 2007 May; 18(5):931-9. PubMed ID: 17395602
[TBL] [Abstract][Full Text] [Related]
31. Clinical implication of genome-wide profiling in diffuse large B-cell lymphoma and other subtypes of B-cell lymphoma.
Iqbal J; Joshi S; Patel KN; Javed SI; Kucuk C; Aabida A; d'Amore F; Fu K
Indian J Cancer; 2007; 44(2):72-86. PubMed ID: 17938484
[TBL] [Abstract][Full Text] [Related]
32. Microarray gene expression analysis of fixed archival tissue permits molecular classification and identification of potential therapeutic targets in diffuse large B-cell lymphoma.
Linton K; Howarth C; Wappett M; Newton G; Lachel C; Iqbal J; Pepper S; Byers R; Chan WJ; Radford J
J Mol Diagn; 2012; 14(3):223-32. PubMed ID: 22446084
[TBL] [Abstract][Full Text] [Related]
33. Colorectal diffuse large B-cell lymphoma: molecular subclassification and prognostic significance of immunoglobulin gene translocation.
Hori Y; Yamamoto H; Nozaki Y; Torisu T; Fujiwara M; Taguchi K; Nishiyama K; Nakamura S; Kitazono T; Oda Y
Hum Pathol; 2020 Feb; 96():67-78. PubMed ID: 31734190
[TBL] [Abstract][Full Text] [Related]
34. Prognostic significance of the immunophenotype versus the International Prognostic Index in aggressive non-Hodgkin's lymphoma.
Intragumtornchai T; Rotnakkarin P; Sutcharitchan P; Wannagrairoj P
Clin Lymphoma; 2003 Jun; 4(1):52-5. PubMed ID: 12837156
[TBL] [Abstract][Full Text] [Related]
35. Refining diffuse large B-cell lymphoma subgroups using integrated analysis of molecular profiles.
Dubois S; Tesson B; Mareschal S; Viailly PJ; Bohers E; Ruminy P; Etancelin P; Peyrouze P; Copie-Bergman C; Fabiani B; Petrella T; Jais JP; Haioun C; Salles G; Molina TJ; Leroy K; Tilly H; Jardin F;
EBioMedicine; 2019 Oct; 48():58-69. PubMed ID: 31648986
[TBL] [Abstract][Full Text] [Related]
36. A new diagnostic algorithm for Burkitt and diffuse large B-cell lymphomas based on the expression of CSE1L and STAT3 and on MYC rearrangement predicts outcome.
Soldini D; Montagna C; Schüffler P; Martin V; Georgis A; Thiesler T; Curioni-Fontecedro A; Went P; Bosshard G; Dehler S; Mazzuchelli L; Tinguely M
Ann Oncol; 2013 Jan; 24(1):193-201. PubMed ID: 22967991
[TBL] [Abstract][Full Text] [Related]
37. Clinical quantitation of diagnostic and predictive gene expression levels in follicular and diffuse large B-cell lymphoma by RT-PCR gene expression profiling.
Sakhinia E; Glennie C; Hoyland JA; Menasce LP; Brady G; Miller C; Radford JA; Byers RJ
Blood; 2007 May; 109(9):3922-8. PubMed ID: 17255358
[TBL] [Abstract][Full Text] [Related]
38. Prognostic significance of serum aspartic transaminase in diffuse large B-cell lymphoma.
Lu TX; Wu S; Cai DY; Hong TT; Zhang Y; Gao HQ; Hua HY; Wu XH
BMC Cancer; 2019 Jun; 19(1):553. PubMed ID: 31176361
[TBL] [Abstract][Full Text] [Related]
39. Discovery and validation of immune-associated long non-coding RNA biomarkers associated with clinically molecular subtype and prognosis in diffuse large B cell lymphoma.
Zhou M; Zhao H; Xu W; Bao S; Cheng L; Sun J
Mol Cancer; 2017 Jan; 16(1):16. PubMed ID: 28103885
[TBL] [Abstract][Full Text] [Related]
40. Biological prognostic markers in diffuse large B-cell lymphoma.
Perry AM; Mitrovic Z; Chan WC
Cancer Control; 2012 Jul; 19(3):214-26. PubMed ID: 22710897
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]